Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 67366
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Pla2g4a
Name: phospholipase A2 group IVA
Acc ID: CHEBI:5118
Term: fluoxetine
Definition: A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
Chemical ID: MESH:D005473
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Pla2g4aincreases expressionISOPla2g4a (Mus musculus)6480464CTDFluoxetine results in increased expression of PLA2G4A mRNA; Fluoxetine results in increased expression of PLA2G4A proteinPMID:19662385
Pla2g4amultiple interactionsISOPla2g4a (Mus musculus)6480464CTD[[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK1 protein] which results in increased expression of PLA2G4A protein; [[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK3 protein] which results in increased expression of PLA2G4A protein; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]; U 0126 inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; U 0126 inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]PMID:19662385
Go Back to source page   Continue to Ontology report